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Abstract
Background: Atomoxetine is FDA-approved as a treatment of attention-deficit/hyperactivity disorder (ADHD)
in patients aged 6 years to adult. Among pediatric clinical trials of atomoxetine to date, six with a randomized,
double-blind, placebo-controlled design were used in this meta-analysis. The purpose of this article is to describe
and compare the treatment response and tolerability of atomoxetine between younger children (6–7 years) and
older children (8–12 years) with ADHD, as reported in these six acute treatment trials.
Methods: Data from six clinical trials of 6–9 weeks duration were pooled, yielding 280 subjects, ages 6–7 years,
and 860 subjects, ages 8–12 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
(DSM-IV)-diagnosed ADHD. Efficacy was analyzed using the ADHD Rating Scale-IV (ADHD-RS), Conners' Parent
Rating Scale-revised (CPRS-R:S), and the Clinical Global Impression of ADHD Severity (CGI-ADHD-S).
Results: Atomoxetine was superior to placebo in both age categories for mean (SD) change in ADHD-RS total,
total T, and subscale scores; 3 CPRS-R:S subscales; and CGI-ADHD-S from baseline. Although there were no
significant treatment differentials between the age groups for these efficacy measures, the age groups themselves,
regardless of treatment, were significantly different for ADHD-RS total (younger: ATX = -14.2 [13.8], PBO = -
4.6 [10.4]; older: ATX = -15.4 [13.2], PBO = -7.3 [12.0]; p = .001), total T (younger: ATX = -15.2 [14.8], PBO =
-4.9 [11.2]; older: ATX = -16.4 [14.6], PBO = -7.9 [13.1]; p = .003), and subscale scores (Inattentive: younger:
ATX = -7.2 [7.5], PBO = -2.4 [5.7]; older: ATX = -8.0 [7.4], PBO = -3.9 [6.7]; p = .043; Hyperactive/Impulsive:
younger: ATX = -7.0 [7.2], PBO = -2.1 [5.4]; older: ATX = -7.3 [7.0], PBO = -3.4 [6.3]; p < .001), as well as the
CGI-ADHD-S score (younger: ATX = -1.2 [1.3], PBO = -0.5 [0.9]; older: ATX = -1.4 [1.3], PBO = -0.7 [1.1]; p =
.010). Although few subjects discontinued from either age group due to adverse events, a significant treatment-
by-age-group interaction was observed for abdominal pain (younger: ATX = 19%, PBO = 6%; older: ATX = 15%,
PBO = 13%; p = .044), vomiting (younger: ATX = 14%, PBO = 2%; older: ATX = 9%, PBO = 6%; p = .053), cough
(younger: ATX = 10%, PBO = 6%; older: ATX = 3%, PBO = 9%; p = .007), and pyrexia (younger: ATX = 5%, PBO
= 2%; older: ATX = 3%, PBO = 5%; p = .058).
Conclusion: Atomoxetine is an effective and generally well-tolerated treatment of ADHD in both younger and
older children as assessed by three recognized measures of symptoms in six controlled clinical trials.
Trial Registration: Not Applicable.
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Background
Attention-deficit/hyperactivity disorder (ADHD) is char-
acterized by developmentally inappropriate levels of inat-
tention, hyperactivity, and impulsivity [1]. In order to
make a diagnosis of ADHD, an onset of impairing symp-
toms is required prior to 7 years of age [1]. Symptoms of
ADHD are often present as young as 3 years of age, with
epidemiological data suggesting that approximately 2% of
children between the ages of 3–5 years meet the Diagnos-
tic and Statistical Manual of Mental Disorders, Fourth Edi-
tion (DSM-IV) diagnostic criteria for ADHD [2].
The preschool and early years of school are times of rapid
growth and development in children. Failing to identify
and treat ADHD early can allow impaired functioning to
persist in multiple domains throughout critical periods of
development. Preschool children with ADHD are at
greater risk for behavioral, academic, social, and family
difficulties relative to their unaffected counterparts. In a
study of 94 preschool children, those with ADHD had
already demonstrated a difference in behavioral ratings
that was two standard deviations greater than the control
group [3]. By the time children with ADHD enter school,
they are likely to be behind their peers without ADHD in
basic math concepts, pre-reading skills, and fine motor
abilities [4-6].
Even with growing awareness of the potential impair-
ments of ADHD in early childhood, limited data exist
regarding its treatment in young children. For example,
despite being one of the largest and most influential stud-
ies of pediatric psychopharmacology to date, the Multi-
modal Treatment Study of Children with ADHD (MTA)
[7] did not include children under the age of 7 years. The
Preschool ADHD Treatment Study (PATS), however,
recently assessed the use of methylphenidate (MPH) in
preschool children with ADHD [8] in an 8-phase, 70-
week, multi-center, randomized efficacy trial. A total of
165 children aged 3.5 to 5.5 years were randomized to
treatment with TID MPH. Significant decreases in ADHD
symptoms were found at MPH doses of 2.5, 5.0, and 7.5
mg TID (p < .01, p < .001, and p < .001, respectively)
when compared with placebo. Effect sizes (0.4–0.8), how-
ever, were smaller than those for school-aged children [8].
Relative to the school-aged children in the MTA Study, the
preschool group in the PATS study demonstrated a higher
rate of emotional adverse effects, including crabbiness,
irritability, and proneness to crying [9].
Atomoxetine (ATX), a selective noradrenergic reuptake
inhibitor, is a non-stimulant medication approved for the
treatment of ADHD in patients 6 years of age through
adulthood. No known controlled studies of non-stimu-
lant medications for young children with ADHD have
been completed to date, although a small open label 8-
week study of ATX in 5- and 6-year old children with
ADHD was recently conducted by Kratochvil, et al. [10].
In this study, 22 children were treated with flexibly dosed
ATX titrated to a maximum of 1.8 mg/kg/day, with a mean
final daily dose of 1.25 mg/kg/day. A significant decrease
was observed on the ADHD-IV-RS-Parent total and sub-
scale scores (p < 0.001). Mood lability, described as
"angry/hostile", "brittle mood", "emotionally labile",
"fussy", "mopey", "rapid mood swings", "tearful" and
"irritability", was reported in over half of the subjects (n =
12, 54.5%), and 50% of subjects reported decreased appe-
tite. There were no discontinuations due to adverse events.
Vital sign changes were mild and not clinically significant;
however, a mean 1.04 kg weight loss was observed for the
group (p < 0.001). A larger randomized placebo-control-
led trial of ATX in 5- and 6-year olds is underway, and will
provide important information on the use of this non-
stimulant medication in a younger population.
Allen and Michelson [11] described the extensive process
related to the development and FDA approval of ATX as a
treatment for ADHD in children. To date, over 4,000 chil-
dren have participated in Eli Lilly sponsored clinical trials
of ATX, including 7 pediatric trials, of which 6 were a ran-
domized, double-blind, placebo-controlled design [12-
14]. This large pool of data allows for the evaluation of
subpopulations and their variations in treatment response
and tolerability. For example, an earlier analysis by Wilens
et al. [15] compared children ages 6–11 to adolescents
12–17, demonstrating no statistically significant differ-
ences in the overall effects on ADHD symptoms, response
rates, or time to response between these age groups. This
report will describe and compare the safety, tolerability
and efficacy of ATX for the treatment of ADHD in young
children, 6–7 years of age, compared with older children,
8–12 years of age.
Methods
Subjects
This report is based upon a meta-analysis of 6 rand-
omized, double-blind, placebo-controlled studies of ATX
that were conducted in the United States [12] between
1998 and 2004[13,14]. Subjects were 6–16 years of age,
although this analysis will focus only on children 6–12
years of age.
Inclusion and Exclusion Criteria
Subjects were assessed using the Kiddie Schedule for
Affective Disorders and Schizophrenia for School-aged
Children, Present and Lifetime Versions (KSADS-PL) [16],
a semi-structured interview for psychiatric disorders. All
subjects were required to meet the DSM-IV [1] diagnostic
criteria for ADHD on the KSADS-PL, which was confirmed
as the primary diagnosis by clinical assessment.Child and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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Although learning disabilities were not exclusionary, sub-
jects were required to be of normal intelligence (IQ ≥ 80)
as assessed by one of the following means: four subtests
(e.g. Block Design, Picture Arrangement, Similarities, and
Vocabulary) of the Wechsler Intelligence Scale for Chil-
dren-3rd Edition (WISC-III) [17], the full WISC-III, or the
general assessment of the physician investigator (studies
HFBK, HFBD and LYAT) [13,14]. In three studies (studies
LYBG, LYBI and LYCC) [12,18,19], the IQ requirement
was  ≥70 based on the investigator's assessment of the
child. Potential subjects with any serious medical illness,
comorbid psychosis or bipolar disorder, history of a sei-
zure disorder, comorbid condition requiring use of
excluded concomitant medications, or ongoing use of
psychoactive medications other than the study drug, were
excluded.
For each subject, a parent or guardian provided written
informed consent to participate and the child provided
written assent, prior to receiving any study treatment or
undergoing any study procedure. These studies met all
federal and local regulatory requirements and were con-
ducted in accordance with the ethical standards of each
investigative site's institutional review board and the Hel-
sinki Declaration of 1975, as revised in 2000 [20].
Measures
The primary outcome measure for all 6 studies was the
ADHD-RS [21], an investigator-administered and scored
instrument that includes the 18 DSM-IV symptom criteria
for ADHD. Each item was rated 0–3 by the investigator
during a semi-structured interview with the parent or pri-
mary caregiver. Subjects were required to have a total
score or subscale score that was ≥1.5 standard deviations
above age and gender norms, depending on their diagnos-
tic subtype (e.g., total score for combined, or subscale
score for primarily inattentive or primarily hyperactive/
impulsive). Other measures included the CPRS-R:S [22],
which contains subscales for oppositional behavior,
hyperactivity and cognition, as well as an ADHD Index,
and the CGI-ADHD-S [23]. The ADHD-RS and the CGI-
ADHD-S were administered at each visit, while the CPRS-
R:S was administered at baseline and again at the final
acute treatment visit in all studies.
Study Design
In 3 studies [12,13,19], the subjects were randomly
assigned to receive either once-daily ATX or placebo
(PBO) for 6 to 8 weeks. In 2 of the studies [12,19] subjects
assigned to ATX received 0.8 mg/kg/day in the morning
for 3 days, after which the dose was increased to 1.2 mg/
kg/day. These subjects were maintained on an "optimal"
dose for 2 to 8 weeks. In the third study [13], subjects
assigned to receive ATX had treatment initiated at a dose
of 0.5 mg/kg/day for 3 days, after which the dose was
increased to 0.75 mg/kg/day for the remainder of the first
week. The daily dose was increased to 1.0 mg/kg/day after
7 days of treatment and maintained on an optimal dose
for 4 to 6 weeks. In all 3 trials, subjects with significant
residual symptomatology (defined as having a CGI-
ADHD score ≥3) after 3 to 4 weeks of ATX treatment and
without safety or tolerability contraindications could have
their dose increased at physician discretion to a maximum
of 1.4/1.8 mg/kg/day.
In 2 of the studies [14], design was identical, PBO or dou-
ble-blinded ATX was dosed twice daily for 9 weeks dura-
tion. The titration was flexible based on therapeutic
response and tolerability. Atomoxetine doses ranged from
5 to 45 mg BID, with a maximum total daily dose of 90
mg/day permitted, and a maximum weight-adjusted daily
dose of 2.0 mg/kg/day. Final visit mean and median doses
of ATX in these combined studies were 1.5 and 1.7 mg/kg/
day, respectively.
In the final study (study LYBI) [18], subjects were rand-
omized to receive one of three treatments, ATX, PBO, or
OROS MPH, for 6 weeks during the acute treatment phase
of the trial (Note: Only data from the ATX and PBO treat-
ment groups are included in the present meta-analysis).
Subjects assigned to ATX initiated treatment at a dose of
0.8 mg/kg/day divided BID for 4 days, which was then
increased to 1.2 mg/kg/day. Similar to the once-daily tri-
als, subjects with significant residual symptomatology
(defined as having CGI-ADHD-S score ≥3) after 3 weeks
of ATX treatment and without safety or tolerability con-
traindications could have their dose increased to a maxi-
mum of 1.8 mg/kg/day.
Data Analysis
Age was dichotomized into two categories: 6–7 years; and
8–12 years. Only subjects aged 6 to 12 years were included
in this analysis, since 12 was the maximum age for inclu-
sion in all but two of the studies (in studies LYBI and LYAT
the maximum age was 16) [13,18]. Patient demographics
and baseline characteristics were summarized using
descriptive statistics. Change from baseline to endpoint,
using a last-observation-carried-forward (LOCF)
approach, was computed for all subjects with baseline and
at least one post-baseline measurement. For continuous
efficacy variables, treatment difference within each age
group was assessed by analysis of covariance (ANCOVA)
with terms for baseline, protocol, and treatment. Using
the ANCOVA model, effect size (ES) was computed by
subtracting the least-squares (LS) means for the PBO
group from the LS means from the ATX group and divid-
ing by the square root of the mean-squared error. In addi-
tion, consistency of treatment effect between age groups
for continuous measures was assessed using an ANCOVAChild and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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model with terms for baseline, protocol, treatment, age
group, and treatment-by-age-group interaction.
Response was defined in two different ways in this meta-
analysis: 1) ≥25% reduction from baseline in ADHD-RS
total score and 2) ADHD-RS total T-scores of < 65. In addi-
tion, remission was defined as ADHD-RS total T-scores of
< 60 at endpoint. For each response and remission rate,
treatment differences within each age group were deter-
mined using a Fisher's exact test, while the Breslow-Day
test compared odds ratios between the age categories for
consistency of treatment effect across the groups. All ran-
domly assigned subjects who took at least one dose of
study drug were included in the safety analysis. Treat-
ment-emergent adverse events (AEs) were defined as
events that had newly occurred or had worsened after ini-
tiating protocol treatment. Treatment-emergent AEs were
analyzed similarly to that of response rate. Although
height and weight were collected, only weight data are
presented due to the short duration of the studies. Pulse
and blood pressure were reported for 3 of the 4 studies,
but methods of collection were varied (e.g. standing and
supine in one study, seated in the other three studies). For
change in weight, vital signs, corrected QT interval, and
laboratory parameters, treatment difference within each
age category was assessed using an ANOVA model with a
treatment term. Consistency of treatment effect across age
groups was assessed using an ANOVA model with terms
for treatment, age group, and treatment-by-age-group
interaction. Since laboratory data tended not to meet nor-
mality assumptions, ranked data were used instead of raw
data in these ANOVA models for all laboratory measures.
All tests were performed using a 2-sided test at a 0.05 sig-
nificance level, with the exception of the treatment-by-
age-group interaction tests, which were performed at a
0.10 significance level. All statistical analyses were per-
formed using SAS software, version 8.2 [24].
Results
Demographics
Demographic characteristics for patients by each age cate-
gory are presented in Table 1. There were 1,140 subjects in
the pooled analysis, of which 280 (25%) were 6–7 years
of age (ATX, n = 184; PBO, n = 96) while 860 patients
(75%) were 8–12 years of age (ATX, n = 544; PBO, n =
316). Seventy-four percent of the subjects were male, and
71% were Caucasian. The mean ages were 7.2 years in the
6- to 7-year-old group and 10.2 years for the 8- to 12-year-
old group. Seventy-three percent of all subjects met crite-
ria for ADHD, combined subtype; 24% were classified as
inattentive subtype and 2% were classified as hyperactive/
impulsive subtype. There were no statistically significant
demographic differences found between ATX and PBO
treatment groups within each age group.
Table 1: Summary of Demographic Characteristics
6- and 7-Year Olds 8- to 12-Year Olds
ATX PBO ATX PBO
Subject Characteristics N = 184 N = 96 pa N = 544 N = 316 pa
Gender, n (%)
Female 54 (29.3) 22 (22.9) .262 137 (25.2) 78 (24.7) .935
Male 130 (70.7) 74 (77.1) 407 (74.8) 238 (75.3)
Age (years), mean (SD) 7.2 (0.6) 7.1 (0.5) . 273b 10.2 (1.4) 10.2 (1.4) .606b
Origin, n (%)
African descent 16 (8.7) 15 (15.6) .179 81 (14.9) 40 (12.7) .442
Caucasian 137 (74.5) 64 (66.7) 374 (68.8) 234 (74.1)
Hispanic 22 (12.0) 9 (9.4) 59 (10.8) 27 (8.5)
Other 9 (4.9) 8 (8.3) 30 (5.5) 15 (4.7)
Prior stimulant treatment, n (%)
No 133 (72.3) 68 (70.8) .889 235 (43.3) 141 (44.6) .722
Yes 51 (27.7) 28 (29.2) 308 (56.7) 175 (55.4)
ADHD Subtype, n (%)
Hyperactive/impulsive 10 (5.4) 2 (2.1) .395 10 (1.8) 5 (1.6) .828
Inattentive 26 (14.1) 12 (12.5) 148 (27.2) 92 (29.1)
Combined 148 (80.4) 82 (85.4) 386 (71.0) 219 (69.3)
ADHD Severity, mean (SD)
Baseline ADHD Total T score 83.4 (9.5) 83.2 (8.7) .862 81.7 (11.6) 81.2 (11.2) .512
Baseline CGI-ADHD-S score 5.0 (0.8) 5.0 (0.7) .743 4.9 (0.8) 4.9 (0.8) .909
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ATX = atomoxetine; PBO = placebo; SD = standard deviation
a p values were for comparing atomoxetine and placebo using a Fisher's exact test.
b p values were for comparing atomoxetine and placebo using an ANOVA.Child and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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Baseline Characteristics
ADHD symptom severity was similar at baseline for both
treatment conditions within each age group, as measured
by the ADHD-RS total T score and the CGI-ADHD-S score.
However, between age groups, younger subjects (6–7
years) experienced more severe ADHD symptoms at base-
line compared with the older subjects (8–12 years). Mean
ADHD-RS total T scores were at least 3 standard devia-
tions above normal in each group. A higher percentage of
children in the older age group met criteria for the inatten-
tive subtype compared with those in the younger group.
More children aged 8–12 years had previously been
treated with a stimulant compared with their younger
counterparts. Comorbid conditions were comparable,
with 34% of the subjects in both age groups meeting diag-
nostic criteria for oppositional defiant disorder (ODD).
Efficacy
Table 2 summarizes the change from baseline to endpoint
for ADHD-RS total score, subscale scores, and total T-
score, CGI-ADHD-S score, and all four CPRS-R:S subscale
scores. With the exception of the CPRS-R:S Oppositional
Table 2: Summary of Efficacy Measures – Change from Baseline to Endpoint
Baseline Change Vs. Placebo Subgroup Treatment by Subgroup
Measure Subgroup (yrs) Tx N Mean SD Mean SD ES p Valuea p Valueb p Valueb
ADHD-RS Total 6–7 ATX 176 42.8 7.9 -14.2 13.8 .77 < .001 .001 .316
PBO 91 43.2 6.6 -4.6 10.4
8–12 ATX 520 40.4 8.7 -15.4 13.2 .65 < .001
PBO 303 40.0 8.2 -7.3 12.0
ADHD-RS Total T-Score 6–7 ATX 176 83.3 9.6 -15.2 14.8 .75 < .001 .003 .346
PBO 91 83.1 8.5 -4.9 11.2
8–12 ATX 520 81.5 11.4 -16.4 14.6 .63 < .001
PBO 303 81.1 10.9 -7.9 13.1
ADHD-RS Inattentive 6–7 ATX 176 21.9 3.8 -7.2 7.5 .71 < .001 .043 .439
PBO 91 22.1 3.7 -2.4 5.7
8–12 ATX 520 22.4 3.7 -8.0 7.4 .59 < .001
PBO 303 22.3 3.9 -3.9 6.7
ADHD-RS Hyper/Impulsive 6–7 ATX 176 20.9 5.6 -7.0 7.2 .76 < .001 < .001 .257
PBO 91 21.2 4.5 -2.1 5.4
8–12 ATX 520 18.0 6.7 -7.3 7.0 .62 < .001
PBO 303 17.7 6.3 -3.4 6.3
CGI-ADHD-S 6–7 ATX 176 5.0 0.8 -1.2 1.3 .62 < .001 .010 .800
PBO 91 5.0 0.7 -0.5 0.9
8–12 ATX 520 4.9 0.8 -1.4 1.3 .59 < .001
PBO 304 4.9 0.8 -0.7 1.1
CPRS-R:S ADHD Index 6–7 ATX 83 27.5 6.0 -7.1 11.2 .50 .009 .723 .422
PBO 42 28.6 5.0 -3.2 8.4
8–12 ATX 290 27.3 6.0 -8.1 8.7 .74 < .001
PBO 188 27.1 6.1 -2.1 8.5
CPRS-R:S Cognitive 6–7 ATX 83 13.7 3.5 -3.6 6.0 .41 .033 .614 .334
PBO 41 14.0 3.3 -1.6 4.8
8–12 ATX 289 13.9 3.8 -4.0 5.1 .69 < .001
PBO 188 13.9 3.8 -0.8 5.2
CPRS-R:S Hyperactive 6–7 ATX 83 12.4 4.3 -3.9 5.7 .56 .004 .095 .753
PBO 42 13.3 3.2 -1.6 4.9
8–12 ATX 290 10.4 5.1 -4.1 4.5 .72 < .001
PBO 188 10.1 4.8 -1.1 4.0
CPRS-R:S Oppositional 6–7 ATX 83 9.4 4.6 -1.9 5.4 .31 .104 .256 .090
PBO 42 8.3 5.0 0.1 3.8
8–12 ATX 290 8.7 4.7 -1.4 4.2 .05 .620
PBO 188 8.8 4.6 -1.2 4.1
Abbreviations: ADHD = attention-deficit/hyperactivity disorder; ADHD-RS = ADHD Rating Scale-IV; ANCOVA = analysis of covariance;
ATX = atomoxetine; CPRS-R:S = Conners' Parent Rating Scale-revised; CGI-ADHD-S = Clinical Global Impression of ADHD Severity scale;
ES = effect size; PBO = placebo; SD = standard deviation.
ap values comparing ATX vs. PBO by subgroup are based on an ANCOVA on change from baseline scores with terms for baseline, protocol, and 
treatment.
bp values for subgroup and treatment-by-subgroup interaction are based on an ANCOVA on change from baseline scores with terms for baseline, 
protocol, treatment, subgroup, and treatment-by-subgroup interaction.Child and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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subscale, ATX-treated subjects in both the younger and
older age groups demonstrated significant improvement
compared with those treated with PBO on all efficacy
measures: ADHD-RS total score: younger ES = .77, older
ES = .65; total T-score: younger ES = .75, older ES = .63;
Inattentive subscale: younger ES = .71, older ES = .59;
Hyperactive/Impulsive subscale: younger ES = .76, older
ES = .62; CGI-ADHD-S score: younger ES = .62, older ES =
.59; CPRS-R:S ADHD Index: younger ES = .50, older ES =
.74; CPRS-R:S Cognition: younger ES = .41, older ES = .69;
CPRS-R:S Hyperactive: younger ES = .56, older ES = .72).
In addition, only the CPRS-R:S Oppositional subscale had
a statistically significant treatment-by-age-group interac-
tion. However, significant age group differences were
observed for ADHD-RS total and subscale scores and CGI-
ADHD-S score, where older children (irrespective of
whether they were treated with ATX or PBO) improved
significantly more than their younger counterparts.
Response rates, defined as ≥25% reduction from baseline
in ADHD-RS total score, were significantly different
between ATX and PBO treatment groups for children 6–7
years (ATX, 55.7%; PBO, 22.0%; p < .001) and children
aged 8–12 years (ATX, 63.5%; PBO, 35.6%; p < .001). No
statistically significant differential treatment effects were
observed between the age groups (p = .287). Response
rates, defined as having endpoint T-scores of < 65, were
significantly different between ATX and PBO treatment
groups for the 6–7 year olds (ATX, 44.3%; PBO, 16.5%; p
< .0001) and the 8–12 year olds (ATX, 51.9%; PBO,
28.4%; p < .0001). The treatment-by-age-group effect was
not significant (p = .270). The percentage of subjects expe-
riencing remission at endpoint, as defined by T-score < 60,
were significantly different between ATX and PBO for
both age groups (6–7 year old ATX, 36.4%, PBO, 8.8%, p
< .0001; 8–12 year old ATX, 41.0%, PBO, 19.8%, p <
.0001). A significant treatment-by-age effect was seen (p =
.0830) in remission rates.
Safety and Tolerability
Atomoxetine was well tolerated by children in both age
groups. The median and mean (standard deviation [SD])
final ATX doses were 1.47 mg/kg/day and 1.39 (0.38) mg/
kg/day for younger children, and 1.44 mg/kg/day and
1.37 (0.40) mg/kg/day for older children. The difference
in final dose was not statistically significant. Rates of study
completion were similar between the two groups
(younger children, 76.4%; older children, 78.5%).
Reasons for discontinuation for subjects receiving ATX or
PBO did not significantly differ within age groups, with
the exception of discontinuation due to lack of efficacy.
Patients who received PBO had a significantly higher rate
of study discontinuation due to lack of efficacy for both
younger (ATX, 1.1%; PBO, 6.3%; p = .021) and older
(ATX, 2.8%; PBO, 9.5%; p < .001) children. Conversely,
incidence of study discontinuation due to AEs was not sig-
nificantly different between treatment groups in younger
(ATX, 1.1%; PBO, 4.2%; p = .186) versus older (ATX,
3.7%; PBO, 1.6%, p = .093) children. However, a signifi-
cant differential treatment effect was observed between
the age groups (p = .015).
Treatment-emergent AEs reported by at least 5% of
patients are presented in Table 3. Younger children taking
ATX versus PBO had significantly higher rates of upper
abdominal pain, decreased appetite, vomiting, and som-
nolence. Among older children, there were significantly
higher rates of decreased appetite, somnolence, irritabil-
ity, and fatigue observed for those taking ATX versus PBO.
Of these treatment-emergent AEs, upper abdominal pain
and vomiting had a significant treatment-by-age-group
interaction. The odds ratio (OR) for treatment-emergent
upper abdominal pain in younger versus older children
was 3.4 and 1.2, respectively (p = 0.044); for vomiting, the
OR was 7.4 and 1.4, respectively, for younger versus older
children (p = 0.053). Of note, a significant treatment dif-
ferential was also observed for pyrexia and cough.
Atomoxetine was associated with a statistically significant
increase in mean (SD) pulse rate for both younger (ATX,
8.7 [12.7]; PBO, 1.0 [13.7]; p = .001) and older (ATX, 6.8
[11.7]; PBO, 0.6 [11.3]; p < .001) subjects. Similarly, a sta-
tistically significant treatment-group difference in systolic
blood pressure (ATX, 2.1 [9.8] mmHg; PBO, 0.3 [8.1]
mmHg; p = .034) and diastolic blood pressure (ATX, 2.9
[8.2] mmHg; PBO, 0.6 [8.0] mmHg; p = .002) was
observed for older children, but not for younger children.
There was no significant treatment-by-age-group interac-
tion observed for either pulse rate, systolic or diastolic
blood pressure. For mean (SD) weight change from base-
line to endpoint, a statistically significant decrease in
weight was observed for children taking ATX compared
with PBO in both age groups (younger: ATX, -0.5 [1.1] kg;
PBO, +0.7 [0.7] kg; older: ATX, -0.6 [1.3] kg; PBO, +1.1
[1.4]; p < .001 for both). In addition, a significant differ-
ential treatment effect between the age groups was
observed for mean weight change (p = .004). There were
no significant differences between the age groups or sig-
nificant treatment-by-age-group interaction for mean
(SD) corrected QT interval (Fridericia's method)
(younger: ATX, -1.0 [21.1] msec; PBO, 0.7 [16.3] msec; p
= .510; older: ATX, -0.9 [18.1] msec; PBO, -1.1 [17.5]
msec; p = .862; interaction p = .485), and no clinically
meaningful differences in laboratory measures.
Discussion
ADHD is a disorder that, by definition, presents at a
young age and generally persists for years with continuing
treatment often recommended. Limited information,Child and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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however, exists regarding the safety and efficacy of phar-
macotherapy for ADHD in children under the age of 8.
The current analysis takes advantage of the growing data-
base from multiple clinical trials of ATX to examine differ-
ences in response and tolerability in younger (6–7 years)
versus older (8–12 years) children with ADHD. In the
absence of trials specifically designed to examine these
outcomes in young children treated with ATX, this meta-
analysis may be the only available means of systematically
assessing the effects of this medication, which is used with
increasing frequency in this patient population.
As anticipated, ATX was effective in reducing core symp-
toms of ADHD in both age groups. There was a statisti-
cally significant improvement compared with placebo for
both age groups in all but one of the efficacy measures.
Combining data from ATX and PBO patients, significant
age group differences were observed for ADHD-RS total
and subscale scores, as well as the CGI-ADHD-S score, in
which older children demonstrated significantly greater
improvement compared with younger children.
While generally well-tolerated by both younger and older
children with ADHD, ATX treatment in the 6- to 7-year-
olds resulted in higher rates of upper abdominal pain,
decreased appetite, vomiting, and somnolence compared
with PBO, while 8- to 12-year-olds experienced higher
rates of decreased appetite, somnolence, irritability, and
fatigue. There were also statistically significant increases in
pulse and decreases in weight for both younger and older
children on ATX treatment compared with PBO. Increases
in systolic and diastolic blood pressures in the older chil-
dren and decreased weight in the younger children,
although statistically significant, were not judged as clini-
cally significant. Nonetheless, increases in mean pulse
and blood pressures, while not generally clinically signif-
icant in this study, are enough to warrant monitoring
when utilizing ATX to treat pediatric patients. The labora-
tory and ECG values revealed no safety concerns, includ-
ing no evidence of hepatotoxicity. These data support the
current guidelines of monitoring children clinically while
on ATX treatment without obtaining baseline or ongoing
laboratory or ECG evaluations unless a specific clinical
presentation is cause for concern (i.e., jaundice, pruritus,
or dark urine).
This analysis is limited by the relatively short duration of
the 6 studies. Patients were treated for 6 to 9 weeks with
either once or twice-daily ATX. Target doses (approxi-
mately 1.2–1.5 mg/kg) were achieved over a range of a few
days to more than two weeks, depending upon the study.
Therefore, maximum benefit from ATX may not have
been achieved by all subjects during the treatment period,
as total time on target dose may have been insufficient.
Procedural variations in timing of doses, titration, dura-
tion of the study, and methods of collecting vital signs
may have limited the ability to combine and/or interpret
the data. Additionally, the omission of a teacher-rated effi-
cacy measure may limit this study's application to a
school-based setting.
Table 3: Summary of Treatment-Emergent Adverse Events Reported by at Least 5% of Subjects in Either Age Group
6- and 7-Year Olds 8- to 12-Year Olds
ATX PBO ATX PBO
N = 183 N = 95 N = 542 N = 316
Event n (%) (n) % p Valuea (n) % (n) % p Valuea p Valueb
Abdominal pain upper 34 (18.6) 6 (6.3) .006 83 (15.3) 40 (12.7) .313 .044
Decreased appetite 30 (16.4) 3 (3.2) < .001 82 (15.1) 17 (5.4) < .001 .331
Headache 25 (13.7) 8 (8.4) .243 90 (16.6) 54 (17.1) .850 .214
Vomiting 25 (13.7) 2 (2.1) .001 51 (9.4) 18 (5.7) .068 .053
Cough 18 (9.8) 6 (6.3) .375 18 (3.3) 28 (8.9) < .001 .007
Nausea 13 (7.1) 2 (2.1) .097 42 (7.7) 20 (6.3) .496 .186
Fatigue 12 (6.6) 2 (2.1) .150 39 (7.2) 8 (2.5) .003 .918
Somnolence 12 (6.6) 1 (1.1) .040 50 (9.2) 14 (4.4) .010 .294
Irritability 9 (4.9) 2 (2.1) .342 33 (6.1) 9 (2.8) .034 .924
Pyrexia 9 (4.9) 2 (2.1) .342 15 (2.8) 17 (5.4) .062 .058
Nasopharyngitis 8 (4.4) 4 (4.2) 1.00 26 (4.8) 24 (7.6) .098 .442
Upper respiratory tract infection 8 (4.4) 3 (3.2) .754 16 (3.0) 17 (5.4) .096 .206
Pharyngolaryngeal pain 2 (1.1) 3 (3.2) .342 26 (4.8) 29 (9.2) .014 .687
Abbreviations: ATX = atomoxetine; N, n = number; PBO = placebo.
aP values comparing ATX and PBO within each subgroup are based on Fisher's exact test.
bP values comparing odds ratios between children and adolescentChild and Adolescent Psychiatry and Mental Health 2008, 2:25 http://www.capmh.com/content/2/1/25
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The long-term safety and efficacy of ATX in young chil-
dren cannot be determined by the results of this analysis.
However, a previous study demonstrated atomoxetine to
be effective and generally well-tolerated in 6- and 7-year-
olds over a period of up to two years [25].
Conclusion
The data presented here suggest that the ADHD symptoms
of children 6–7 years old improve with ATX treatment,
with a more effective overall response compared with that
seen in children 8–12 years old. The side effect profile of
ATX differed slightly in the younger versus older children,
with few study discontinuations from either group due to
AEs. These data are important in making clinicians aware
that, in general, the response and tolerability of ATX treat-
ment did not vary significantly between these two age
groups. However, the potential for these differences must
be taken into account when assessing the risk/benefit rela-
tionship of the medication and making treatment deci-
sions. Atomoxetine use may warrant additional care and
surveillance when treating younger children, about whom
we have very limited information. Further research is war-
ranted, particularly to examine atomoxetine long-term
safety and efficacy, in the treatment of young children
with ADHD.
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